Loading...
•
Dec 31, 2021
Corbus Pharmaceuticals Q4 2021 Earnings Report
Corbus Pharmaceuticals reported financial results for the fourth quarter and year-end of 2021.
Key Takeaways
Corbus Pharmaceuticals reported a net loss of approximately $10.3 million for the three months ended December 31, 2021. The company's cash and investments on hand of $98.3 million is expected to fund operations into the first quarter of 2024.
Company is advancing its integrin program and on schedule for initiating clinical studies in 2023
Expanding immuno-oncology pipeline through strategic transactions remains key priority
Cash and investments on hand of $98.3 million funds operations into the first quarter of 2024
Hired Rachael Brake, Ph.D., as Chief Scientific Officer, strengthening the Company's capabilities to expand and develop its innovative immuno-oncology pipeline
Corbus Pharmaceuticals
Corbus Pharmaceuticals
Forward Guidance
Corbus Pharmaceuticals is focused on advancing its integrin program and expanding its immuno-oncology pipeline through strategic transactions. The company's cash and investments are expected to fund operations into the first quarter of 2024.
Positive Outlook
- Company is advancing its integrin program and on schedule for initiating clinical studies in 2023
- Expanding immuno-oncology pipeline through strategic transactions remains key priority
- Cash and investments on hand of $98.3 million funds operations into the first quarter of 2024
- Hired Rachael Brake, Ph.D., as Chief Scientific Officer, strengthening the Company's capabilities to expand and develop its innovative immuno-oncology pipeline
- Anti-integrin monoclonal antibodies (mAbs) program targeting the inhibition of TGFβ is progressing on schedule.